Sustained Anti-Staphylococcal Effect of Lysostaphin in the Rabbit Aqueous Humor

REFERENCES

• Patel A, Calfee RP, Plante M, et al. Methicillin-resistant Staphylococcus aureus in orthopaedic surgery. J Bone Joint Surg Br 2008;90:1401–1406.
   PubMedGoogle Scholar
• Guay DR. Contemporary management of uncomplicated urinary tract infections. Drugs 2008;68:1169–1205.
   PubMed Web of Science ®Google Scholar
• Kalita O, Kala M, Svebisova H, et al. Glioblastoma multiforme with an abscess: case report and literature review. J Neurooncol 2008;88:221–225.
   Google Scholar
• Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46 Suppl 5:S378–S385.
   PubMed Web of Science ®Google Scholar
• Climo MW, Patron RL, Goldstein BP, Archer GL. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother 1998;42:1355–1360.
   PubMed Web of Science ®Google Scholar
• Shanmuganathan VA, Armstrong M, Buller A, Tullo AB. External ocular infections due to methicillin-resistant Staphylococcus aureus (MRSA). Eye (Lond) 2005;19:284–291.
   PubMed Web of Science ®Google Scholar
• Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:1–17.
   PubMed Web of Science ®Google Scholar
• Giese MJ, Mondino BJ. Experimental staphylococcal endophthalmitis. Ophthalmologica 2001;215:321–336.
   Google Scholar
• Callegan MC, Engelbert M, Parke DW 2nd, Jett BD, Gilmore MS. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev 2002;15:111–124.
   PubMed Web of Science ®Google Scholar
• Gregory M, Callegan MC, Gilmore MS. Role of bacterial and host factors in infectious endophthalmitis. Chem Immunol Allergy 2007;92:266–275.
   PubMedGoogle Scholar
• Deramo VA, Lai JC, Winokur J, Luchs J, Udell IJ. Visual outcome and bacterial sensitivity after methicillin-resistant Staphylococcus aureus-associated acute endophthalmitis. Am J Ophthalmol 2008;145:413–417.
   PubMed Web of Science ®Google Scholar
• Hanscom TA. Postoperative endophthalmitis. Clin Infect Dis 2004;38:542–546.
   PubMed Web of Science ®Google Scholar
• Mao LK, Flynn HW Jr, Miller D, Pflugfelder SC. Endophthalmitis caused by Staphylococcus aureus. Am J Ophthalmol 1993;116:584–589.
   PubMed Web of Science ®Google Scholar
• Ferro JF, de-Pablos M, Logroño MJ, Guisasola L, Aizpuru F. Postoperative contamination after using vancomycin and gentamicin during phacoemulsification. Arch Ophthalmol 1997;115:165–170.
   Google Scholar
• Mather R, Stewart JM, Prabriputaloong T, Wong J, McLeod SD. The effect of cataract surgery on ocular levels of topical moxifloxacin. Am J Ophthalmol 2004;138:554–559.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Nicholson S, Quah SA, et al. Pharmacokinetics of vancomycin following intracameral bolus injection in patients undergoing phacoemulsification cataract surgery. Br J Ophthalmol 2007;91:1350–1353.
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Kobayakawa S, Tsuji A, Tochikubo T. Preventive effect against post-cataract endophthalmitis: drug delivery intraocular lens versus intracameral antibiotics. Curr Eye Res 2008;33:868–875.
   PubMed Web of Science ®Google Scholar
• Trayer HR, Buckley CE 3rd. Molecular properties of lysostaphin, a bacteriolytic agent specific for Staphylococcus aureus. J Biol Chem 1970;245:4842–4846.
   PubMedGoogle Scholar
• Kusuma CM, Kokai-Kun JF. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:3256–3263.
   PubMed Web of Science ®Google Scholar
• Schindler CA, Schuhardt VT. Lysostaphin: a new bacteriolytic agent for the staphylococcus. Proc Natl Acad Sci USA 1964;51:414–421.
   PubMed Web of Science ®Google Scholar
• Browder HP, Zygmunt WA, Young JR, Tavormina PA. Lysostaphin: enzymatic mode of action. Biochem Biophys Res Commun 1965;19:383–389.
   PubMedGoogle Scholar
• von Eiff C, Kokai-Kun JF, Becker K, Peters G. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood. Antimicrob Agents Chemother 2003;47:3613–3615.
   PubMed Web of Science ®Google Scholar
• Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother 2003;47:3407–3414.
   PubMed Web of Science ®Google Scholar
• McCormick CC, Dajcs JJ, Reed JM, Marquart ME, O’Callaghan RJ. The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis. Curr Eye Res 2006;31:225–230.
   Web of Science ®Google Scholar
• Yang XY, Li CR, Lou RH, et al. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China. J Med Microbiol 2007;56:71–76.
   Google Scholar
• Baba T, Schneewind O. Target cell specificity of a bacteriocin molecule: a C-terminal signal directs lysostaphin to the cell wall of Staphylococcus aureus. EMBO J 1996;15:4789–4797.
   PubMed Web of Science ®Google Scholar
• Francius G, Domenech O, Mingeot-Leclercq MP, Dufrêne YF. Direct observation of Staphylococcus aureus cell wall digestion by lysostaphin. J Bacteriol 2008;190:7904–7909.
   PubMed Web of Science ®Google Scholar
• Dajcs JJ, Thibodeaux BA, Girgis DO et al. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Invest Ophthalmol Vis Sci 2002;43:3712–3716.
   PubMed Web of Science ®Google Scholar
• Dajcs JJ, Hume EB, Moreau JM, et al. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci 2000;41:1432–1437.
   PubMed Web of Science ®Google Scholar
• Dajcs JJ, Thibodeaux BA, Hume EB, et al. Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit. Curr Eye Res 2001;22:451–457.
   PubMed Web of Science ®Google Scholar
• Devriese LA. A simplified system for biotyping Staphylococcus aureus strains isolated from animal species. J Appl Bacteriol 1984;56:215–220.
   PubMedGoogle Scholar
• Smyth DS, Feil EJ, Meaney WJ, et al. Molecular genetic typing reveals further insights into the diversity of animal-associated Staphylococcus aureus. J Med Microbiol 2009;58:1343–1353.
   Google Scholar
• Balzli CL, McCormick CC, Caballero AR, Newman E, O’Callaghan RJ. A new Staphylococcus aureus rabbit endophthalmitis model and the effectiveness of fourth generation fluoroquinolones. Ocular Microbiology and Immunology Group 2008: E-Abstract Number 6.
   Google Scholar
• Caballero AR, Stroman DW, Bartell JG, Balzli CL, O’Callaghan RJ. Genetic analysis of a new Staphylococcus aureus isolate that exhibits exquisite virulence in the rabbit cornea, conjunctiva and anterior chamber. Invest Ophthalmol Vis Sci. 2009;50: ARVO E-Abstract 5112.
   Google Scholar
• Balzli CL, McCormickCC Caballero, AR, Tang A, O’Callaghan RJ. A rabbit model of Staphylococcus aureus anterior chamber infection and the effectiveness of prophylactic therapy. Invest Ophthalmol Vis Sci. 2009;50: ARVO E-Abstract 3019.
   Google Scholar
• Wada T, Kozai S, Tajika T, et al. Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits. J Ocul Pharmacol Ther 2008;24:278–289.
   PubMed Web of Science ®Google Scholar
• Kiri N, Archer G, Climo MW. Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother 2002;46:2017–2020.
   PubMed Web of Science ®Google Scholar
• Climo MW, Ehlert K, Archer GL. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001;45:1431–1437.
   PubMed Web of Science ®Google Scholar
• Walsh S, Shah A, Mond J. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob Agents Chemother 2003;47:554–558.
   PubMed Web of Science ®Google Scholar
• Niederkorn JY. The induction of anterior chamber-associated immune deviation. Chem Immunol Allergy 2007;92:27–35.
   Google Scholar
• Stein-Streilein J, Watte C. Cross talk among cells promoting anterior chamber-associated immune deviation. Chem Immunol Allergy 2007;92:115–130.
   Google Scholar
• Zhang-Hoover J, Stein-Streilein J. Therapies based on principles of ocular immune privilege. Chem Immunol Allergy 2007;92:317–327.
   Google Scholar
• Stein-Streilein J, Streilein JW. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int Rev Immunol 2002;21:123–152.
   PubMedGoogle Scholar
• Zygmunt WA, Browder HP, Tavormina PA. Lytic action of lysostaphin on susceptible and resistant strains of Staphylococcus aureus. Can J Microbiol 1967;13:845–853.
   PubMed Web of Science ®Google Scholar
• Ehlert K, Schröder W, Labischinski H. Specificities of FemA and FemB for different glycine residues: FemB cannot substitute for FemA in staphylococcal peptidoglycan pentaglycine side chain formation. J Bacteriol 1997;179:7573–7576.
   Google Scholar
• Strandén AM, Ehlert K, Labischinski H, Berger-Bächi B. Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J Bacteriol 1997;179:9–16.
   PubMed Web of Science ®Google Scholar
• Rohrer S, Berger-Bächi B. FemABX peptidyl transferases: a link between branched-chain cell wall peptide formation and beta-lactam resistance in gram-positive cocci. Antimicrob Agents Chemother 2003;47:837–846.
   PubMed Web of Science ®Google Scholar